Effects of dexborneol on pharmacokinetics of edaravone in cerebral ischemic stroke rats
- VernacularTitle:右莰醇对缺血性脑卒中大鼠体内依达拉奉药代动力学的影响
- Author:
Juan HAO
1
;
Zhiqiang MENG
2
;
Xiaoxiao TIAN
2
;
Xueli DUAN
2
;
Miao HOU
2
;
Fang WANG
2
;
Ruigang HOU
2
Author Information
1. Dept. of Pharmacy，The Second Hospital of Shanxi Medical University，Taiyuan 030001，China;College of Pharmacy，Shanxi Medical University，Taiyuan 030001，China
2. Dept. of Pharmacy，The Second Hospital of Shanxi Medical University，Taiyuan 030001，China
- Publication Type:Journal Article
- Keywords:
cerebral ischemic stroke;
Edaravone;
dexborneol;
pharmacokinetics;
UPLC-MS/MS method
- From:
China Pharmacy
2026;37(20):2706-2710
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effects of dexborneol on the pharmacokinetic parameters of edaravone in rats under the pathological condition of cerebral ischemic stroke （CIS）.METHODS Twenty male SD rats were randomly divided into the edaravone group and the Edaravone and dexborneol concentrated solution for injection （EDB injection） group， with 10 rats in each group. A middle cerebral artery occlusion （MCAO） rat model was established using the modified Longa suture method. Within 5 min of ischemia-reperfusion， the corresponding drug solutions were injected via the tail vein at a dose of 2.5 mg/kg （calculated by edaravone）. Blood samples were collected from the orbital venous plexus at 0.08， 0.5， 1， 3， 6， 18， and 24 h after injection. With carbamazepine as the internal standard， the plasma concentration of edaravone was determined by ultra-performance liquid chromatography-tandem mass spectrometry （UPLC-MS/MS） method. Pharmacokinetic parameters were calculated using DAS software and compared between the two groups.RESULTS Compared with the edaravone group， the peak concentration （ c max ） of edaravone in the EDB injection group was significantly increased （ P ＜0.05）， while no statistically significant differences were observed in the half life， time to peak， clearance， or area under curve （ P ＞0.05）.CONCLUSIONS Under the pathological condition of CIS， dexborneol can increase the c max of edaravone in the plasma of model rats， but has no significant effect on the systemic exposure or clearance of edaravone.
